Ease of opening of blistered solid dosage forms in a senior citizens target group

Braun-Münker, Myriam; Ecker, Felix

doi:10.1016/j.ijpharm.2015.10.063

Cited by 12 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Technologies for improving the swallowability of SODF have been developed and tested throughout the years; nevertheless, these often require preparative steps by the patient and, as such, remain very dependent on user's handling capabilities. When considering the older, multimorbid, frail, and polymedicated patients; this might further increase the therapeutic complexity and lead to non-compliance or medication errors [211][212][213][214]. It was noticed that all of the clinical assessments were sponsored, or at least supported, by companies owning the swallowing enhancing technology under investigation.…”

Section: Discussionmentioning

confidence: 99%

Better Medicines for Older Patients: Considerations between Patient Characteristics and Solid Oral Dosage Form Designs to Improve Swallowing Experience

Drumond

Stegemann

2020

Pharmaceutics

View full text Add to dashboard Cite

Oral drug administration provided as solid oral dosage forms (SODF) remains the major route of drug therapy in primary and secondary care. There is clear evidence for a growing number of clinically relevant swallowing issues (e.g., dysphagia) in the older patient population, especially when considering the multimorbid, frail, and polymedicated patients. Swallowing impairments have a negative impact on SODF administration, which leads to poor adherence and inappropriate alterations (e.g., crushing, splitting). Different strategies have been proposed over the years in order to enhance the swallowing experience with SODF, by using conventional administration techniques or applying swallowing aids and devices. Nevertheless, new formulation designs must be considered by implementing a patient centric approach in order to efficiently improve SODF administration by older patient populations. Together with appropriate SODF size reductions, innovative film coating materials that can be applied to SODF and provide swallowing safety and efficacy with little effort being required by the patients are still needed. With that in mind, a literature review was conducted in order to identify the availability of patient centric coating materials claiming to shorten esophageal transit times and improve the overall SODF swallowing experience for older patients. The majority of coating technologies were identified in patent applications, and they mainly included well-known water soluble polymers that are commonly applied into pharmaceutical coatings. Nevertheless, scientific evidence demonstrating the benefits of given SODF coating materials in the concerned patient populations are still very limited. Consequently, the availability for safe, effective, and clinically proven solutions to address the increasing prevalence of swallowing issues in the older patient population is still limited.

show abstract

Section: Discussionmentioning

confidence: 99%

Better Medicines for Older Patients: Considerations between Patient Characteristics and Solid Oral Dosage Form Designs to Improve Swallowing Experience

Drumond

Stegemann

2020

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Further, the patient may suffer negative effects of poor disease control due to the decreased self-management ability (Philbert, 2014). Packaging development should therefore target for high patient satisfaction to ensure convenient use (Braun-Münker, 2016). Guidelines for packaging manufacturers recommend that 95% of the consumers must be able to handle the products adequately (Marks, 2012).…”

Section: Discussionmentioning

confidence: 99%

Learning from Parkinson’s patients: Usability of the Cyclops dry powder inhaler

Luinstra

Isufi

Jong

et al. 2019

International Journal of Pharmaceutics

View full text Add to dashboard Cite

“…The overall patient medication burden increases with every additional medicinal product prescribed, especially if products have to be taken at different times in the day (morning, lunch, dinner and before bedtime) or according to different user instructions (2 h before or after a meal or on the opposite, with some food), require different handlings (one tablet to be taken intact and another tablet for chewing) or caregiver assistance (e.g., when an older person is unable to measure a liquid dose, to break a tablet or to self-administer eye drops). 5,44,45 A high patient burden commonly results in problems in medication management and patient adherence and increases the risk for medication errors. Therefore, the RP states that the added burden of a new medicine (and medicinal product) has to be carefully considered.…”

Section: Section 231-237 Preparations For Specific Routes Of Administ...mentioning

confidence: 99%

“…Difficulties in the ease of opening packaging such as plastic or glass bottles, blisters, eye drops and the effect this may have on patient adherence, medication safety and quality of life are well described. 5,45,46 Therefore, the RP considers that the ease of opening containers or administering products through the container or device itself should be confirmed for all products likely to be used by older people. Although not clearly stated in this RP, it is evident that also the disease status needs to be considered.…”

Section: Section 25: Excipients In the Formulationmentioning

confidence: 99%

Commentary on the EMA reflection paper on the pharmaceutical development of medicines for use in the older population

Riet‐Nales

Bemt

Bodegom

et al. 2022

Brit J Clinical Pharma

View full text Add to dashboard Cite

Funding information Medicines Evaluation BoardOlder people are often affected by impaired organ and bodily functions resulting in multimorbidity and polypharmacy, turning them into the main user group of many medicines. Very often, medicines have not specifically been developed for older people, causing practical medication problems for them like limited availability of easy to swallow formulations, easy to open packaging and dosing instructions for enteral administration. In 2020, the European Medicines Agency (EMA) published a reflection paper 'Pharmaceutical development of medicines for use in the older population', which discusses how the emerging needs of an ageing European population can be addressed by medicines regulation. The paper intends to help industry to better consider the needs of older people during pharmaceutical/clinical medicines development by summarising data on the most relevant topics, providing early suggestions on how to move forward and prompting expert discussions and studies into knowledge gaps. Topics include patient acceptability, (dis)advantages of an administration route, formulation, dosage form, packaging, dosing device and user instruction. While the paper is directed at older people and the pharmaceutical industry, the reflections

show abstract

Ease of opening of blistered solid dosage forms in a senior citizens target group

Cited by 12 publications

References 0 publications

Better Medicines for Older Patients: Considerations between Patient Characteristics and Solid Oral Dosage Form Designs to Improve Swallowing Experience

Better Medicines for Older Patients: Considerations between Patient Characteristics and Solid Oral Dosage Form Designs to Improve Swallowing Experience

Learning from Parkinson’s patients: Usability of the Cyclops dry powder inhaler

Commentary on the EMA reflection paper on the pharmaceutical development of medicines for use in the older population

Contact Info

Product

Resources

About